Lexaria Bioscience Corp. Files 8-K: Board & Officer Changes
Ticker: LEXX · Form: 8-K · Filed: Sep 5, 2024
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
TL;DR
Lexaria Bioscience Corp. filed an 8-K on Aug 31, 2024, detailing board/officer changes and compensation.
AI Summary
Lexaria Bioscience Corp. filed an 8-K on August 31, 2024, reporting changes in its board of directors and executive officers, along with updates on compensatory arrangements. The filing also includes financial statements and exhibits, and a Regulation FD disclosure. The company, incorporated in Nevada, operates in the pharmaceutical preparations sector.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and executive compensation can introduce uncertainty and signal potential strategic shifts, requiring closer investor scrutiny.
Key Players & Entities
- Lexaria Bioscience Corp. (company) — Registrant
- August 31, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
FAQ
What specific changes were made to the board of directors or certain officers?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', but the specific details of these changes are not provided in the excerpt.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
A Regulation FD Disclosure ensures that material non-public information is broadly disseminated to the public, preventing selective disclosure to certain investors.
What type of business does Lexaria Bioscience Corp. operate in?
Lexaria Bioscience Corp. operates in the 'PHARMACEUTICAL PREPARATIONS' sector, with SIC code 2834.
When was the company incorporated and what is its fiscal year end?
The company was incorporated in Nevada and its fiscal year ends on August 31.
What is the filing date and the period of report for this 8-K?
The filing date is September 5, 2024, and the conformed period of report is August 31, 2024.
Filing Stats: 1,435 words · 6 min read · ~5 pages · Grade level 11.6 · Accepted 2024-09-05 10:11:19
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
- $120,000 — transaction with the Company exceeding $120,000. Mr. Christopher has extensive experi
- $3 — ve an exercise price per share equal to $3.92, being one cent ($0.01) above the cl
- $0.01 — r share equal to $3.92, being one cent ($0.01) above the closing price of the Company
Filing Documents
- lxrp_8k.htm (8-K) — 35KB
- lxrp_ex991.htm (EX-99.1) — 25KB
- lxrp_ex991img2.jpg (GRAPHIC) — 3KB
- lxrp_ex991img3.jpg (GRAPHIC) — 44KB
- 0001640334-24-001396.txt ( ) — 273KB
- lxrp-20240831.xsd (EX-101.SCH) — 6KB
- lxrp-20240831_lab.xml (EX-101.LAB) — 16KB
- lxrp-20240831_cal.xml (EX-101.CAL) — 1KB
- lxrp-20240831_pre.xml (EX-101.PRE) — 12KB
- lxrp-20240831_def.xml (EX-101.DEF) — 4KB
- lxrp_8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure Christopher Bunka, the outgoing Chief Executive Officer of Lexaria Bioscience Corp. ("Lexaria") has issued his final letter providing Lexaria's strategic update. A copy of the letter is attached as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits 99.1 Letter from the CEO 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ John Docherty John Docherty President Date: September 5, 2024 4